These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
414 related items for PubMed ID: 31049766
1. Evolution of the Use of Completion Axillary Lymph Node Dissection in Patients with T1/2N0M0 Breast Cancer and Tumour-Involved Sentinel Lymph Nodes Undergoing Mastectomy: A Cohort Study. Hennigs A, Riedel F, Feißt M, Köpke M, Rezai M, Nitz U, Moderow M, Golatta M, Sohn C, Heil J. Ann Surg Oncol; 2019 Aug; 26(8):2435-2443. PubMed ID: 31049766 [Abstract] [Full Text] [Related]
2. Which patients with sentinel node-positive breast cancer after breast conservation still receive completion axillary lymph node dissection in routine clinical practice? Hennigs A, Köpke M, Feißt M, Riedel F, Rezai M, Nitz U, Moderow M, Golatta M, Sohn C, Schneeweiss A, Heil J. Breast Cancer Res Treat; 2019 Jan; 173(2):429-438. PubMed ID: 30315437 [Abstract] [Full Text] [Related]
4. Eight-year follow up result of the OTOASOR trial: The Optimal Treatment Of the Axilla - Surgery Or Radiotherapy after positive sentinel lymph node biopsy in early-stage breast cancer: A randomized, single centre, phase III, non-inferiority trial. Sávolt Á, Péley G, Polgár C, Udvarhelyi N, Rubovszky G, Kovács E, Győrffy B, Kásler M, Mátrai Z. Eur J Surg Oncol; 2017 Apr; 43(4):672-679. PubMed ID: 28139362 [Abstract] [Full Text] [Related]
5. Locoregional Management of the Axilla in Mastectomy Patients with One or Two Positive Sentinel Nodes: The Role of Intraoperative Pathology. Davis J, Boughey JC, Hoskin TL, Day CN, Cheville JC, Piltin MA, Hieken TJ. Clin Breast Cancer; 2021 Oct; 21(5):458-465. PubMed ID: 33839043 [Abstract] [Full Text] [Related]
6. Non-sentinel axillary tumor burden applying the ACOSOG Z0011 eligibility criteria to a large routine cohort. Riedel F, Heil J, Feißt M, Rezai M, Moderow M, Sohn C, Schütz F, Golatta M, Hennigs A. Breast Cancer Res Treat; 2019 Sep; 177(2):457-467. PubMed ID: 31236814 [Abstract] [Full Text] [Related]
8. Omitting completion axillary lymph node dissection after detection of sentinel node micrometastases in breast cancer: first results from the prospective SENOMIC trial. Andersson Y, Bergkvist L, Frisell J, de Boniface J. Br J Surg; 2021 Sep 27; 108(9):1105-1111. PubMed ID: 34010418 [Abstract] [Full Text] [Related]
10. Omitting axillary lymph node dissection after positive sentinel lymph node in the post-Z0011 era: Compliance with NCCN and ASCO clinical guidelines and Z0011 criteria in a large prospective cohort. Costaz H, Boulle D, Bertaut A, Rouffiac M, Beltjens F, Desmoulins I, Peignaux K, Ladoire S, Causeret S, Loustalot C, Padeano MM, Vincent L, Jankowski C, Arnould L, Coutant C. Bull Cancer; 2022 Mar 27; 109(3):268-279. PubMed ID: 34838310 [Abstract] [Full Text] [Related]
11. When is a completion axillary lymph node dissection necessary in the presence of a positive sentinel lymph node? Suyoi A, Bains SK, Kothari A, Douek M, Agbaje O, Hamed H, Fentiman I, Pinder S, Purushotham AD. Eur J Cancer; 2014 Mar 27; 50(4):690-7. PubMed ID: 24331957 [Abstract] [Full Text] [Related]